Copyright
©The Author(s) 2016.
World J Gastroenterol. Jul 28, 2016; 22(28): 6393-6401
Published online Jul 28, 2016. doi: 10.3748/wjg.v22.i28.6393
Published online Jul 28, 2016. doi: 10.3748/wjg.v22.i28.6393
Table 1 Drugs for hepatitis C virus treatment
| Mechanism of action | Drug | Genotype |
| Protease inhibitor | Telaprevir | 1 |
| Boceprevir | 1 | |
| Simeprevir | 1 | |
| Paritaprevir | 1, 4 | |
| Grazoprevir | 1, 4 | |
| Asunaprevir1 | 1 | |
| ABT-4501 | 1 | |
| Faldaprevir1 | 1 | |
| NS5A inhibitors | Daclatasvir | 1, 3 |
| Ombitasvir | 1, 4 | |
| Ledipasvir | 1, 4, 5, 6 | |
| Elbasvir | 1, 4 | |
| Velpatasvir1 | 4 | |
| NS5B inhibitors | ||
| Nucleotide-analogue | Sofosbuvir | 1, 2, 3, 4, 5, 6 |
| Non-nucleoside analogue | Dasabuvir | 1 |
| Beclabuvir1 | 1 |
Table 2 Treatments for hepatitis C virus infection
| Ref. | Treatment, wk | Genotype | SVR (total, cirrhotic, non-cirrhotic) | Previously treated |
| Patients included | ||||
| Davis et al[53] | IFN, 24 | 1 | 3; NA; NA | Yes |
| IFN + RBV, 24 | 30; NA; NA | |||
| IDEAL Study Team[54] | PEG-IFN/RBV, 48 | 1 | 39.8-40.9; 42.1-43.6; 20.7-23.6 | No |
| ADVANCE Study Team[48] | TVR + PEG-IFN/RBV | 1 | 75; 62-81; 62 | No |
| REALIZE Study Team[49] | TVR + PEG-IFN/RBV, 48 | 1 | 63-64; 28-84; NA | Yes |
| SPRINT-2 Investigators[47] | BOC + PEG-IFN/RBV, 28 | 1 | 67; 70; 50 | No |
| BOC + PEG-IFN/RBV, 48 | 68; 70; 50 | |||
| RESPOND-2 Investigators[46] | BOC + PEG-IFN/RBV, 36 | 1 | 59; 35; 64 | Yes |
| BOC + PEG-IFN/RBV, 48 | 66; 77; 66 | |||
| PILLAR[55] | SMP + PEG-IFN/RBV, 12 | 1 | 80.5; NA; 80.5 | No |
| SMP + PEG-IFN/RBV, 24 | 86.1; NA; 86.1 | |||
| Gane et al[56] | SOF + RBV, 12 | 2 or 3 | 100; NA; 100 | No |
| SOF + PEG-IFN/RBV, 8 | 100; NA; 100 | |||
| COSMOS[57] | SMP + SOF + RBV, 24 | 1 | NA; 93;79 | Yes |
| SMP + SOF, 24 | NA; 93; 100 | |||
| SMP + SOF + RBV, 12 | NA; 93; 93 | |||
| SMP + SOF, 12 | NA; 90; 94 | |||
| OPTIMIST-1[58] | SMP + SOF, 8 | 1 | 83; NA; 83 | Yes |
| SMP + SOF, 12 | 97; NA; 97 | |||
| OPTIMIST-2[59] | SMP + SOF, 12 | 1 | 83; 83; NA | Yes |
| AI444040 Study group[60] | DCV + SOF, 24 | 2 or 3 | 100; NA; NA | No |
| DCV + SOF + RBV, 24 | 86; NA; NA | No | ||
| DCV + SOF, 24 | 1 | 100; NA; NA | Yes | |
| DCV + SOF + RBV, 24 | 95-100; NA; NA | |||
| ALLY-3 Study Team[61] | DCV + SOF, 12 | 3 | 86-91; 63; 96 | Yes |
| ION-2 Investigators[62] | LDV + SOF, 12 | 1 | 94; 86; 97 | Yes |
| LDV + SOF, 24 | 99; 100; 99 | |||
| LDV + SOF + RBV, 12 | 96; 87; 100 | |||
| LDV + SOF + RBV, 24 | 99; 100; 99 | |||
| ION-3 Investigators[63] | LDV + SOF, 8 | 1 | 94; NA; 94 | No |
| LDV + SOF + RBV, 8 | 93; NA; 93 | |||
| LDV + SOF, 12 | 95; NA; 95 | |||
| MALACHITE-I/II[64] | OBV + PTV/r + DSV + RBV, 12 | 1 | 97-99; NA; 97-99 | Yes |
| PEARL-I[65] | OBV + PTV/r | 4 | 91; NA; 91 | No |
| OBV + PTV/r + RBV | 100; NA; 100 | Yes | ||
| SAPPHIRE-II[66] | ABT-450/r + OBV + DSV + RBV, 12 | 1 | 96.3; NA; 93.6 | Yes |
| TURQUOISE-II[67] | ABT-450/r + OBV + DSV + RBV, 12 | 1 | 91.8; 91.8; NA | Yes |
| ABT-450/r + OBV + DSV + RBV, 24 | 95.9; 95.9; NA | |||
| ASTRAL-2 and ASTRAL-3[68] | SOF + VEL, 12 | 2 | 99; 100; 99 | Yes |
| 3 | 95; 93; 98 | |||
| C-WORTHY[69] | GZR + EBR, 12 | 1 | 91-97; 91-97; NA | Yes |
| GZR + EBR + RBV, 12 | 90-94; 90-94; NA | |||
| GZR + EBR, 18 | 94-97; NA; NA | |||
| GZR + EBR + RBV, 18 | 97-100; NA; NA | |||
| Everson et al[70] | DCV + ASV + BCV, 12 | 1 | 88.8-89.5; 71.4-100; 87.5-91.1 | No |
| DCV + ASV + BCV + RBV, 12 | 85.7; 100; 85 | |||
| SOUND-2[71] | FDV + deleobuvir + RBV, 16 | 1 | 59; NA; NA | No |
| FDV + deleobuvir + RBV, 28 | 59-69; NA; NA | |||
| FDV + deleobuvir + RBV, 40 | 52; NA; NA | |||
| FDV + deleobuvir, 28 | 39; NA; NA |
- Citation: Bastos JCS, Padilla MA, Caserta LC, Miotto N, Vigani AG, Arns CW. Hepatitis C virus: Promising discoveries and new treatments. World J Gastroenterol 2016; 22(28): 6393-6401
- URL: https://www.wjgnet.com/1007-9327/full/v22/i28/6393.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i28.6393